Prelude Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Prelude Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-300	Closed	-$23K	–	1327
2020 Q3	$23K	Sell	300 -100	-25%	-$10.1K	﹤0.01%	1302
2020 Q2	$49K	Buy	+400	New	+$39.8K	﹤0.01%	1165
2018 Q1	–	Sell	-1,000	Closed	-$89K	–	1508
2017 Q4	$89K	Sell	1,000 -500	-33%	-$43.5K	0.01%	810
2017 Q3	$140K	Buy	1,500 +1,000	+200%	+$88.4K	0.01%	761
2017 Q2	$45K	Hold	500	–	–	﹤0.01%	1034
2017 Q1	$44K	Buy	+500	New	+$44.5K	﹤0.01%	1038

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prelude Capital Management's BMRN Position: Q4 2025 in Review

Prelude Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,317 shares — an estimated $288K sold.

Prelude Capital Management first reported a position in BMRN in Q2 2013 and held it in 35 quarters. The position peaked at $1.52M in Q4 2022. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Prelude Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Prelude Capital Management sold 5,317 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $288K.
Prelude Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 35 quarters.
Prelude Capital Management's BioMarin Pharmaceuticals position peaked at $1.52M in Q4 2022.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.